

REMARKS

Applicants amended Claim 13 and 34, as detailed above. Applicants reserve the right to file divisional applications to any subject matter cancelled herein.

35 U.S.C § 112 (1st Par.) Rejection of Claims 7, 9, 13, 33-35 and 37-38.

The Examiner rejected Claims 7, 9, 13, 33-35 and 37-38 under 35 U.S.C. § 112 (1st Par.), contending that the specification is not enabling, because the specification does not provide information for one skilled in the art to "prevent" MED in patients that are not suffering from MED.

Applicants amended Claim 13, adding the phrase "in need thereof" to clarify that the human or animal is in need of treatment and/or prevention of MED. Applicants believe this amendment obviates the 35 U.S.C. § 112 (1st Par.) rejection. Accordingly, Claims 7, 9, 13, 33-35, 37 and 38 are in a condition for allowance.

35 U.S.C § 112 (1st Par.) Rejection of Claims 34-35 and 37-38.


The Examiner rejected Claims 34-35 and 37-38 under 35 U.S.C. § 112 (1st Par.), contending that the specification is not enabling for the agents disclosed in the instant specification. Applicants amended Claim 34 to limit the secondary agents to PDE inhibitors. Applicants believe this amendment obviates the 35 U.S.C. § 112 (1st Par.) rejection. Accordingly, Applicants respectfully submit that Claims 7, 9, 13, 33-35, 37 and 38 are in a condition for allowance.

CONCLUSION

Applicants respectfully request entry of the amendments herein above, and consideration of the remarks above.

Respectfully submitted,

Date: Oct. 13, 2005
Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860)715-4288


Martha G. Munchhof
Attorney for Applicant(s)
Reg. No. 47,811